Interview, Other
A Vaccine-Led Recovery
- A vaccine is projected to receive approval by the end of the current year, with distribution commencing in the following year and the economic impact becoming perceptible from the second quarter of 2021, potentially extending beyond.
- Efficacy rates are anticipated to exceed the optimistic end of existing predictions, contributing an estimated two percentage points of GDP growth by the end of 2021 for the US and Europe, while the effect in China is expected to be positive but smaller.
- Goldman Sachs Research has adopted an optimistic scenario in its central case as of September, forecasting that asset markets will transition to a view of stronger growth by mid to late spring, with a sharp acceleration expected from the second quarter onwards.
- Equities are predicted to rise, particularly in cyclical sectors and emerging markets, while bond yields are expected to increase and the US dollar is forecast to weaken against cyclically sensitive currencies.
- Commodity-related segments and emerging market areas are identified as undervalued relative to optimistic growth views, with expectations that they will outperform as the direct and indirect growth impacts of the vaccine become fully recognized.
- Despite the optimistic long-term outlook, near-term growth forecasts for the US and Europe have been downgraded for a period of several months, necessitating policy support as a bridge to the vaccine's realization.
- The economic recovery may be delayed by distribution and operational challenges, creating potential market volatility and investor opportunities over the next few months while the forward view on vaccine impacts is validated.